clinical trial · NCT07637162
Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia
FibromyalgiaAXS-14 (esreboxetine)
brief summary
This is a Phase 3, multi-center, 52-week, open-label trial to evaluate the long-term safety and efficacy of AXS-14 in the management of fibromyalgia.
started
Apr 29, 2026
primary completion
May 1, 2028
completion
May 1, 2028
last updated
Oct 13, 2026
detailed description
Eligible subjects will have previously participated in the AXS-14-FM-301 (FORWARD) study. Subjects in this open-label extension trial will receive open-label AXS-14 for up to 52 weeks.
official title
An Open-Label Study to Assess the Long-Term Safety and Efficacy of AXS-14 in the Management of Fibromyalgia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol